**Core Concept**
Medullary carcinoma of the thyroid is a type of cancer originating from the parafollicular cells (also known as C cells) of the thyroid gland. These cells produce calcitonin, a hormone involved in calcium homeostasis. Effective management of this condition requires targeted therapy that inhibits the growth of cancer cells.

**Why the Correct Answer is Right**
The management of medullary carcinoma of the thyroid involves the use of tyrosine kinase inhibitors, which target the RET proto-oncogene. The RET gene is a key regulator of cell growth and division, and mutations in this gene are commonly found in medullary thyroid carcinoma. By inhibiting the RET kinase, these drugs prevent the uncontrolled cell growth characteristic of cancer. A notable example of a RET inhibitor used in this context is vandetanib, which has shown efficacy in clinical trials.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is not a specific RET inhibitor used in the management of medullary carcinoma of the thyroid.
* **Option B:** This option is not a recognized treatment for medullary carcinoma of the thyroid.
* **Option D:** This option is not a RET inhibitor and is not used in the management of medullary carcinoma of the thyroid.

**Clinical Pearl / High-Yield Fact**
When managing medullary carcinoma of the thyroid, it is essential to consider genetic testing for RET mutations, as this can inform treatment decisions and provide valuable prognostic information.

**Correct Answer: C. Vandetanib**